You are here: Industry Insights > pembrolizumab

News List

US expands reach of Keytruda in NSCLC pharmatimes
November 05, 2018
US regulators have approved MSD’s Keytruda, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of ...
First-line Keytruda shows better overall survival in head & neck cancer pharmafile
November 01, 2018
MSD’s Keytruda (pembrolizumab) made an impact at the European Society for Medical Oncology 2018 Congress as the company unveiled new Phase 3 data into its efficacy in the first-line treatment...
Alkermes Initiates Evaluation of ALKS 4230 in Combination with Pembrolizumab americanpharmaceuticalreview
September 11, 2018
Alkermes has expanded its ongoing phase 1 study for ALKS 4230, the company's immuno-oncology drug candidate, to evaluate its safety and anti-tumor activity when administered in combination with the FDA-approved PD-1 inhibitor Keytruda (pembrolizumab) in p
NICE backing for Keytruda in classical Hodgkin lymphoma pharmatimes
July 27, 2018
The National Institute for Health and Care Excellence has recommended that MSD’s Keytruda be funded on the NHS via the Cancer Drugs Fund (CDF) for a subgroup of people with relapsed or refractory classical Hodgkin lymphoma.
Keytruda extends survival in first-line head and neck cancer trial pharmatimes
July 26, 2018
MSD’s Keytruda significantly extended overall survival when used as monotherapy for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients expressing PD-L1.
Keytruda/chemo combo cut risk of death in NSCLC pharmatimes
July 16, 2018
MSD has unveiled further data from a trial showing that a combination of Keytruda and chemotherapy significantly improved overall survival in patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).
NICE deems MSD’s Keytruda cost-effective as first-line lung cancer therapy pharmatimes
July 06, 2018
MSD’s Keytruda will be available on the NHS for specific patients with previously untreated metastatic non-small-cell lung cancer, after NHS England struck a deal with the company, endorsed by NICE, to ensure its cost-effectiveness.
Pembrolizumab shows hope for cancerous gestational trophoblastic disease europeanpharmaceuticalreview
November 27, 2017
An immunotherapy drug can be used to cure a rare type of cancer arising from pregnancy when existing treatments have failed…
Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer academic.oup.com
July 24, 2017
After adjusting for inflation, the price per life-year gained of cancer drugs rose from $54 100 to $207 000 over the 20-year time period between 1995 and 2013 (1).
Boehringer Ingelheim to Evaluate Afatinib in Combination with PD-1 Inhibitor Pembrolizumab in New Tr americanpharmaceuticalreview
February 10, 2017
Boehringer Ingelheim has announced the initiation of a Phase II trial of afatinib (Gilotrif®) in combination with pembrolizumab (Keytruda®) for patients with locally advanced or metastatic squamous cell carcinoma (SqCC) of the lung.

Previous page 1 2 3 4 Next page